The Oncologist · 2019 · 33 citations · 29 references
MedicinePharmacologyPharmacotherapyChemotherapyOncology PharmacotherapyPharmacokinetics Of Anticancer AgentsAdverse Effects Of ChemotherapyAntiemetic PharmacologyAntiemetic TherapyNausea ControlNausea ManagementVomiting ControlAcute Chemotherapy-induced NauseaAntiemetic TolerabilityChemotherapy Toxicity PreventionChemotherapy-induced Nausea PreventionChemotherapy-induced Vomiting PreventionNausea And Vomiting ControlNausea In Advanced CancerPharmacokinetics Of Cytotoxic Chemotherapy
Abstract Background NEPA, a combination antiemetic of a neurokinin-1 (NK1) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5-HT3RA, palonosetron] offers 5-day CINV prevention with a single dose. Fosnetupitant solution contains no allergenic excipients, surfactant, emulsifier, or solubility enhancer. A phase III study of patients receiving cisplatin found no infusion-site or anaphylactic reactions related to IV NEPA. However, hypersensitivity reactions and anaphylaxis have been reported with other IV NK1RAs, particularly fosaprepitant in patients receiving anthracycline-cyclophosphamide (AC)-based chemotherapy. This study evaluated the safety and efficacy of IV NEPA in the AC setting. Materials and Methods This phase IIIb, multinational, randomized, double-blind study enrolled females with breast cancer naive to highly or moderately emetogenic chemotherapy. Patients were randomized to receive a single 30-minute infusion of IV NEPA or single oral NEPA capsule on day 1 prior to AC, in repeated (up to 4) cycles. Oral dexamethasone was given to all patients on day 1 only. Results A total of 402 patients were included. The adverse event (AE) profiles were similar for IV and oral NEPA and consistent with those expected. Most AEs were mild or moderate with a similarly low incidence of treatment-related AEs in both groups. There were no treatment-related injection-site AEs and no reports of hypersensitivity or anaphylaxis. The efficacy of IV and oral NEPA were similar, with high complete response (no emesis/no rescue) rates observed in cycle 1 (overall [0–120 hours] 73.0% IV NEPA, 77.3% oral NEPA) and maintained over subsequent cycles. Conclusion IV NEPA was highly effective and safe with no associated hypersensitivity and injection-site reactions in patients receiving AC.
29
Fausto Roila, Alex Molassiotis, Jørn Herrstedt et al. · Annals of Oncology · 2016 · 580 citations · Full text
David Warr, Paul J. Hesketh, Richard J. Gralla et al. · Journal of Clinical Oncology · 2005 · 465 citations
Medicine, Oncology, Pharmacology +17
Quality of life consequences of chemotherapy-induced emesis
Celeste Lindley, Jan D. Hirsch, Casey O'Neill et al. · Quality of Life Research · 1992 · 257 citations
Medicine, Oncology, Pharmacology +14
Matti Aapro, H. S. Rugo, Giada Rizzi et al. · Annals of Oncology · 2014 · 248 citations · Full text